SMYD3 and colorectal carcinoma: The reduced chromatin-binding ability of SMYD3/c-MYC complexes upon EM127 treatment prompted us to evaluate whether SMYD3 activity was required for its physical interaction with c-MYC in patient-derived CRC-SCs.